FILE - Equipment used to test for perfluoroalkyl and polyfluoroalkyl substances, known collectively as PFAS, in drinking water is seen at Trident Laboratories in Holland, Mich., June 18, 2018. Drinking water from nearly half of U.S. faucets likely contains “forever chemicals” linked to kidney cancer and other health problems, according to a government study released Wednesday, July 5, 2023. (Cory Morse/The Grand Rapids Press via AP, File)
TRAVERSE CITY, Mich. (AP) — Drinking water from nearly half of U.S. faucets likely contains “forever chemicals” that may cause cancer and other health problems, according to a government study released Wednesday.
The synthetic compounds known collectively as PFAS are contaminating drinking water to varying extents in large cities and small towns — and in private wells and public systems, the U.S. Geological Survey said.
Researchers described the study as the first nationwide effort to test for PFAS in tap water from private sources in addition to regulated ones. It builds on previous scientific findings that the chemicals are widespread, showing up in consumer products as diverse as nonstick pans, food packaging and water-resistant clothing and making their way into water supplies.
Because the USGS is a scientific research agency, the report makes no policy recommendations. But the information “can be used to evaluate risk of exposure and inform decisions about whether or not you want to treat your drinking water, get it tested or get more information from your state" about the situation locally, said lead author Kelly Smalling, a research hydrologist.
The U.S. Environmental Protection Agency in March proposed the first federal drinking water limits on six forms of PFAS, or per- and polyfluorinated substances, which remain in the human body for years and don't degrade in the environment. A final decision is expected later this year or in 2024.
But the government hasn't prohibited companies using the chemicals from dumping them into public wastewater systems, said Scott Faber, a senior vice president of the Environmental Working Group, an advocacy organization.
“We should be treating this problem where it begins, instead of putting up a stoplight after the accident," he said. “We should be requiring polluters to treat their own wastes.”
Studies of lab animals have found potential links between PFAS chemicals and some cancers, including kidney and testicular, plus issues such as high blood pressure and low birth weight.
Federal and state programs typically measure exposure to pollutants such as PFAS at water treatment plants or groundwater wells that supply them, Smalling said. In contrast, the USGS report was based on samples from taps in 716 locations, including 447 that rely on public supplies and 269 using private wells.
The samples were taken between 2016 and 2021 in a range of locations — mostly residences but also a few schools and offices. They included protected lands such as national parks; residential and rural areas with no identified PFAS sources; and urban centers with industry or waste sites known to generate PFAS.
Most taps were sampled just once. Three were sampled multiple times over a three-month period, with results changing little, Smalling said.
Scientists tested for 32 PFAS compounds — most of the ones detectable through available methods. Thousands of others are believed to exist but can't be spotted with current technology, Smalling said.
The types found most often were PFBS, PFHxS and PFOA. Also making frequent appearances was PFOS, one of the most common nationwide.
Positive samples contained as many as nine varieties, although most were closer to two. The median concentration was around seven parts per trillion for all 32 PFAS types, although for PFOA and PFOS it was about four parts per trillion — the limit EPA has proposed for those two compounds.
The heaviest exposures were in cities and near potential sources of the compounds, particularly in the Eastern Seaboard; Great Lakes and Great Plains urban centers; and Central and Southern California. Many of the tests, mostly in rural areas, found no PFAS.
Based on the data, researchers estimated that at least one form of PFAS could be found in about 45% of tap water samples nationwide.
The study underscores that private well users should have their water tested for PFAS and consider installing filters, said Faber of the Environmental Working Group. Filters containing activated carbon or reverse osmosis membranes can remove the compounds.
The USGS study is “further evidence that PFAS is incredibly pervasive and folks who rely on private wells are particularly vulnerable to the harms caused by these chemicals,” Faber said.
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
